People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
Eli Lilly said it would invest $3 billion to expand a recently ... a study that claimed that its Zepbound obesity drug is ...